These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 28498022

  • 1. Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future.
    Delitala AP, Delitala G, Sioni P, Fanciulli G.
    Curr Med Res Opin; 2017 Nov; 33(11):1985-1993. PubMed ID: 28498022
    [Abstract] [Full Text] [Related]

  • 2. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia.
    Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B.
    N Engl J Med; 2010 Mar 11; 362(10):906-16. PubMed ID: 20220185
    [Abstract] [Full Text] [Related]

  • 3. Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders.
    Saponaro F, Sestito S, Runfola M, Rapposelli S, Chiellini G.
    Front Med (Lausanne); 2020 Mar 11; 7():331. PubMed ID: 32733906
    [Abstract] [Full Text] [Related]

  • 4. Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges.
    Elbers LP, Kastelein JJ, Sjouke B.
    Curr Atheroscler Rep; 2016 Mar 11; 18(3):14. PubMed ID: 26886134
    [Abstract] [Full Text] [Related]

  • 5. Sobetirome: a selective thyromimetic for the treatment of dyslipidemia.
    Tancevski I, Demetz E, Eller P.
    Recent Pat Cardiovasc Drug Discov; 2011 Jan 11; 6(1):16-9. PubMed ID: 21208155
    [Abstract] [Full Text] [Related]

  • 6. Thyromimetics: a journey from bench to bed-side.
    Tancevski I, Rudling M, Eller P.
    Pharmacol Ther; 2011 Jul 11; 131(1):33-9. PubMed ID: 21504761
    [Abstract] [Full Text] [Related]

  • 7. Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease.
    Zhao M, Xie H, Shan H, Zheng Z, Li G, Li M, Hong L.
    Int J Mol Sci; 2022 Jan 20; 23(3):. PubMed ID: 35163026
    [Abstract] [Full Text] [Related]

  • 8. The resurgence of thyromimetics as lipid-modifying agents.
    Tancevski I, Eller P, Patsch JR, Ritsch A.
    Curr Opin Investig Drugs; 2009 Sep 20; 10(9):912-8. PubMed ID: 19705333
    [Abstract] [Full Text] [Related]

  • 9. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 Sep 20; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 10. Sobetirome: the past, present and questions about the future.
    Lammel Lindemann J, Webb P.
    Expert Opin Ther Targets; 2016 Sep 20; 20(2):145-9. PubMed ID: 26565124
    [Abstract] [Full Text] [Related]

  • 11. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans.
    Berkenstam A, Kristensen J, Mellström K, Carlsson B, Malm J, Rehnmark S, Garg N, Andersson CM, Rudling M, Sjöberg F, Angelin B, Baxter JD.
    Proc Natl Acad Sci U S A; 2008 Jan 15; 105(2):663-7. PubMed ID: 18160532
    [Abstract] [Full Text] [Related]

  • 12.
    Lozano P, Henrikson NB, Morrison CC, Dunn J, Nguyen M, Blasi P, Whitlock EP.
    ; 2016 08 15. PubMed ID: 27559550
    [Abstract] [Full Text] [Related]

  • 13. Lipid lowering with thyroid hormone and thyromimetics.
    Angelin B, Rudling M.
    Curr Opin Lipidol; 2010 Dec 15; 21(6):499-506. PubMed ID: 20935564
    [Abstract] [Full Text] [Related]

  • 14. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
    Cariou B, Staels B.
    Expert Opin Investig Drugs; 2014 Oct 15; 23(10):1441-8. PubMed ID: 25164277
    [Abstract] [Full Text] [Related]

  • 15. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R, Di Pino A, Ferrara V, Urbano F, Piro S, Rabuazzo AM, Purrello F.
    Acta Diabetol; 2018 Mar 15; 55(3):209-218. PubMed ID: 29260404
    [Abstract] [Full Text] [Related]

  • 16. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr 15; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 17. An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-α mediated apolipoprotein A-I, A-II and C-III.
    Liu C, Guo Q, Lu M, Li Y.
    Eur J Pharmacol; 2015 Aug 15; 761():362-74. PubMed ID: 25979856
    [Abstract] [Full Text] [Related]

  • 18. Thyroid hormone analogues: where do we stand in 2013?
    Meruvu S, Ayers SD, Winnier G, Webb P.
    Thyroid; 2013 Nov 15; 23(11):1333-44. PubMed ID: 23915136
    [Abstract] [Full Text] [Related]

  • 19. Combination lipid therapy in type 2 diabetes mellitus.
    Vergès B.
    Expert Opin Pharmacother; 2011 Jun 15; 12(9):1393-403. PubMed ID: 21323502
    [Abstract] [Full Text] [Related]

  • 20. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
    Zhao S, Wang Y, Mu Y, Yu B, Ye P, Yan X, Li Z, Wei Y, Ambegaonakr BM, Hu D, DYSIS-China Study Investigators.
    Atherosclerosis; 2014 Aug 15; 235(2):463-9. PubMed ID: 24950001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.